Research and treatment strategies in first-episode psychoses

The Pittsburgh experience

M. S. Keshavan, N. R. Schooler, J. A. Sweeney, G. L. Haas, J. W. Pettegrew

Research output: Contribution to journalArticle

Abstract

Background: Studies of first-episode patients allow investigation of the biological basis of psychotic disorders without the potential confounds of prior treatment and illness chronicity. Prospective studies of this population can clarify the impact of illness course and treatment on neurobiology. Method: We summarize preliminary findings from our ongoing magnetic resonance imaging and spectroscopy studies of first-episode schizophrenia patients being conducted prospectively from index evaluations through a period of two years; during this period, patients were treated with either a conventional antipsychotic such as haloperidol, or the atypical risperidone. Results: Baseline neurobiological evaluations in first-episode schizophrenia patients have revealed evidence for structural and functional brain abnormalities consistent with a neurodevelopmental model of this illness. Our preliminary data support the value of risperidone as an antipsychotic drug of first choice among patients with early schizophrenic illness. Conclusions: Focused studies of first-episode patients have the potential to unravel pathophysiology of schizophrenic illness. Such knowledge is critical for more effective early detection, intervention and even prevention of this enigmatic disorder.

Original languageEnglish (US)
Pages (from-to)60-65
Number of pages6
JournalBritish Journal of Psychiatry
Volume172
Issue numberJUNE SUPPL. 33
StatePublished - 1998

Fingerprint

Psychotic Disorders
Research
Risperidone
Antipsychotic Agents
Schizophrenia
Therapeutics
Neurobiology
Haloperidol
Magnetic Resonance Spectroscopy
Magnetic Resonance Imaging
Prospective Studies
Brain
Population

ASJC Scopus subject areas

  • Neuroscience(all)
  • Psychiatry and Mental health

Cite this

Keshavan, M. S., Schooler, N. R., Sweeney, J. A., Haas, G. L., & Pettegrew, J. W. (1998). Research and treatment strategies in first-episode psychoses: The Pittsburgh experience. British Journal of Psychiatry, 172(JUNE SUPPL. 33), 60-65.

Research and treatment strategies in first-episode psychoses : The Pittsburgh experience. / Keshavan, M. S.; Schooler, N. R.; Sweeney, J. A.; Haas, G. L.; Pettegrew, J. W.

In: British Journal of Psychiatry, Vol. 172, No. JUNE SUPPL. 33, 1998, p. 60-65.

Research output: Contribution to journalArticle

Keshavan, MS, Schooler, NR, Sweeney, JA, Haas, GL & Pettegrew, JW 1998, 'Research and treatment strategies in first-episode psychoses: The Pittsburgh experience', British Journal of Psychiatry, vol. 172, no. JUNE SUPPL. 33, pp. 60-65.
Keshavan, M. S. ; Schooler, N. R. ; Sweeney, J. A. ; Haas, G. L. ; Pettegrew, J. W. / Research and treatment strategies in first-episode psychoses : The Pittsburgh experience. In: British Journal of Psychiatry. 1998 ; Vol. 172, No. JUNE SUPPL. 33. pp. 60-65.
@article{948f62c2fc11404791194dabb54392f8,
title = "Research and treatment strategies in first-episode psychoses: The Pittsburgh experience",
abstract = "Background: Studies of first-episode patients allow investigation of the biological basis of psychotic disorders without the potential confounds of prior treatment and illness chronicity. Prospective studies of this population can clarify the impact of illness course and treatment on neurobiology. Method: We summarize preliminary findings from our ongoing magnetic resonance imaging and spectroscopy studies of first-episode schizophrenia patients being conducted prospectively from index evaluations through a period of two years; during this period, patients were treated with either a conventional antipsychotic such as haloperidol, or the atypical risperidone. Results: Baseline neurobiological evaluations in first-episode schizophrenia patients have revealed evidence for structural and functional brain abnormalities consistent with a neurodevelopmental model of this illness. Our preliminary data support the value of risperidone as an antipsychotic drug of first choice among patients with early schizophrenic illness. Conclusions: Focused studies of first-episode patients have the potential to unravel pathophysiology of schizophrenic illness. Such knowledge is critical for more effective early detection, intervention and even prevention of this enigmatic disorder.",
author = "Keshavan, {M. S.} and Schooler, {N. R.} and Sweeney, {J. A.} and Haas, {G. L.} and Pettegrew, {J. W.}",
year = "1998",
language = "English (US)",
volume = "172",
pages = "60--65",
journal = "British Journal of Psychiatry",
issn = "0007-1250",
publisher = "Royal College of Psychiatrists",
number = "JUNE SUPPL. 33",

}

TY - JOUR

T1 - Research and treatment strategies in first-episode psychoses

T2 - The Pittsburgh experience

AU - Keshavan, M. S.

AU - Schooler, N. R.

AU - Sweeney, J. A.

AU - Haas, G. L.

AU - Pettegrew, J. W.

PY - 1998

Y1 - 1998

N2 - Background: Studies of first-episode patients allow investigation of the biological basis of psychotic disorders without the potential confounds of prior treatment and illness chronicity. Prospective studies of this population can clarify the impact of illness course and treatment on neurobiology. Method: We summarize preliminary findings from our ongoing magnetic resonance imaging and spectroscopy studies of first-episode schizophrenia patients being conducted prospectively from index evaluations through a period of two years; during this period, patients were treated with either a conventional antipsychotic such as haloperidol, or the atypical risperidone. Results: Baseline neurobiological evaluations in first-episode schizophrenia patients have revealed evidence for structural and functional brain abnormalities consistent with a neurodevelopmental model of this illness. Our preliminary data support the value of risperidone as an antipsychotic drug of first choice among patients with early schizophrenic illness. Conclusions: Focused studies of first-episode patients have the potential to unravel pathophysiology of schizophrenic illness. Such knowledge is critical for more effective early detection, intervention and even prevention of this enigmatic disorder.

AB - Background: Studies of first-episode patients allow investigation of the biological basis of psychotic disorders without the potential confounds of prior treatment and illness chronicity. Prospective studies of this population can clarify the impact of illness course and treatment on neurobiology. Method: We summarize preliminary findings from our ongoing magnetic resonance imaging and spectroscopy studies of first-episode schizophrenia patients being conducted prospectively from index evaluations through a period of two years; during this period, patients were treated with either a conventional antipsychotic such as haloperidol, or the atypical risperidone. Results: Baseline neurobiological evaluations in first-episode schizophrenia patients have revealed evidence for structural and functional brain abnormalities consistent with a neurodevelopmental model of this illness. Our preliminary data support the value of risperidone as an antipsychotic drug of first choice among patients with early schizophrenic illness. Conclusions: Focused studies of first-episode patients have the potential to unravel pathophysiology of schizophrenic illness. Such knowledge is critical for more effective early detection, intervention and even prevention of this enigmatic disorder.

UR - http://www.scopus.com/inward/record.url?scp=0031807329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031807329&partnerID=8YFLogxK

M3 - Article

VL - 172

SP - 60

EP - 65

JO - British Journal of Psychiatry

JF - British Journal of Psychiatry

SN - 0007-1250

IS - JUNE SUPPL. 33

ER -